{"entity":{"id":"cullinan-therapeutics","kind":"company","name":"Cullinan Therapeutics","aka":[],"tldr":"Cullinan develops T-cell engager antibodies, which pull a patient's T cells onto target cells, for both cancer and autoimmune disease. Its cancer lead, CLN-049, targets FLT3 on acute myeloid leukaemia cells and is entering a potentially registrational trial.","summary":"Cullinan Therapeutics is a Cambridge, Massachusetts clinical-stage company advancing T-cell engagers (TCEs) in autoimmune disease and cancer. In oncology, CLN-049 is a FLT3xCD3 TCE for relapsed or refractory acute myeloid leukaemia; after a positive End-of-Phase 1 meeting with the FDA in July 2026 a potentially registrational phase 2 study is due to begin in the third quarter of 2026. Autoimmune programmes include CLN-978 (CD19xCD3 TCE) in lupus, rheumatoid arthritis and Sjogren's disease, and velinotamig (BCMAxCD3 TCE) in lupus, with phase 2 expansion studies planned for early 2027. The company reported $356 million in cash and investments at 30 June 2026 with runway into 2029. Nasdaq: CGEM.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://cullinantherapeutics.com/"},{"label":"Q2 2026 results (8-K exhibit 99.1)","url":"https://www.sec.gov/Archives/edgar/data/1789972/000119312526336700/cgem-ex99_1.htm"}],"tags":[],"related":[],"cancers":["aml"],"sections":["immunotherapy"],"technologies":["t-cell-engager","bispecific-antibody"],"targets":["flt3","cd3","cd19","bcma"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04036682"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No funding round sourced. Other oncology assets (for example zipalertinib) not covered by the fetched release and therefore omitted."],"hq":"Cambridge, MA","country":"US","companyType":"biotech","website":"https://cullinantherapeutics.com/","ticker":"CGEM","stage":"public","investors":[],"funding":[]},"route":"/companies/cullinan-therapeutics/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"target":[{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/"},{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"},{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"},{"id":"flt3","kind":"target","name":"FLT3","route":"/targets/flt3/"}],"trial":[{"id":"nct04036682","kind":"trial","name":"A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer","route":"/trials/nct04036682/"}]}}